Soligenix, Inc. (SNGX)
| Market Cap | 2.24M |
| Revenue (ttm) | 699,210 |
| Net Income (ttm) | -7.01M |
| Shares Out | 987.49K |
| EPS (ttm) | -11.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,027 |
| Open | 2.460 |
| Previous Close | 2.490 |
| Day's Range | 2.000 - 2.555 |
| 52-Week Range | 2.030 - 32.000 |
| Beta | 1.93 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2024 |
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inf... [Read more]
Financial Performance
In 2023, Soligenix's revenue was $839,359, a decrease of -11.55% compared to the previous year's $948,911. Losses were -$6.14 million, -55.50% less than in 2022.
Financial StatementsNews
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J. , June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Sol...
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches PRINCETON, N.J., June 14, 2024 /PRNewswire/ -- Soligenix, Inc. (...
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show...
Soligenix Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmac...
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bi...
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PRINCETON, N.J. , May 24, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
Most shareholders can vote by calling 1-833-782-7145 PRINCETON, N.J. , May 23, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company fo...
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
PRINCETON, N.J. , May 21, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
Annual Meeting to be held May 23, 2024 PRINCETON, N.J., May 20, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo...
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
Published Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J. , May 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bi...
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
PRINCETON, N.J. , May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Soligenix to Present at Upcoming Conferences
PRINCETON, N.J. , May 6, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Includes thermostabilized Ebola vaccines MarVax™ and SuVax™ Includes nanoemulsion adjuvant compatible with lyophilization PRINCETON, N.J. , April 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX...
Soligenix Announces Pricing of $4.75 Million Public Offering
PRINCETON, N.J. , April 18, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing product...
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company...
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Provides SuVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 11, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company...
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study PRINCETON, N.J. , April 3, 2024 /PRNewswire/ -- Sol...
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
PRINCETON, N.J. , March 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J. , Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharm...
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / January 26, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show, ...
Soligenix to Present at The Microcap Conference
PRINCETON, N.J. , Jan. 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
PRINCETON, N.J. , Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Clinical Success Achieved in Second Cohort of Patients PRINCETON, N.J. , Jan. 4, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company ...
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses PRINCETON, N.J. , Jan. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix o...
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON, N.J. , Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...